Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06159244

Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients

In humans, alcohol-related dysbiosis exists with a decrease in bacteroides. This dysbiosis is responsible for the breakdown of the intestinal barrier by a decrease in the synthesis of protective mucus, and some proteins involved in tight junctions or a decrease in defensin (Reg3b, Reg3g) which promotes bacterial growth and ultimately bacterial translocation. The microbiota of a patient with alcoholic hepatitis is different from that of a patient without alcoholic hepatitis. Acute alcoholic hepatitis has a severe prognosis and corticosteroids are the only first line therapy option, with better survival at 28 days versus placebo. However, mortality remains high at 30% at 3 months, which highlights the importance of seeking intestinal microbiota profile on treatment response.

The determination of one or more intestinal microbiota signatures associated with the treatment response Corticosteroids plus FMT or Corticosteroids plus placebo will allow the clinician to have a simple and rapid test obtained in 16S RNA analysis to predict the therapeutic response and potentially the best treatment to adopt and to address medical and medico-economic stakes.

The investigators will first characterize the alcohol-induced dysbiosis by a whole microbiota sequencing in the different groups. Specific bacterial species identify by DNA sequencing should be confirmed by qPCR of 16S rDNA to determine a fingerprint of sAH microbiota. Metabolic properties of intestinal microbiota, such as production of short chain fatty acids, will be analyzed by using HPLC. In the sAH group, evolution of intestinal microbiota will be observed by shotgun DNA sequencing between the day 0 and the day 7 of corticosteroids treatment.

The analysis of sAH patients' microbiota (day 0) will allow us to obtain a non-responder profile to corticosteroids that can be used as a prognostic marker to use in the clinic. The deliverable is the bacterial fingerprint of the treatment response and its valuation is its use as a predictive tool of the response.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Severe Acute Alcoholic Hepatitis Alcohol Corticosteroids Intestinal Microbiota

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens Picardie

Amiens, Picardie, 80054, France

Location status: Recruiting

Location contact

Eric NGUYEN KHAC, PhD

CONTACT

[email protected]

+33322668883

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged from 18 to 75 years, having :
  • Heavy drinker with Maddrey Score ≥ 32 : PT(second)-PT(control)x4.6+Bilirubine (mg/dl)
  • Histological confirmed Alcoholic hepatitis
  • Personal consent signed to the trial
  • No exclusion criteria

Exclusion criteria

  • Age < 18 years and/or > 75 years,
  • Pregnancy or lactating females,
  • No personal consent
  • Other causes of liver disease: chronic hepatitis B (antigen HBs positive), hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, autoimmune hepatitis, primary biliary cholangitis, primary sclerosis cholangitis, alpha 1 antitrypsine deficiency, and Wilson disease.
  • Uncontrolled liver complications:
  • Upper gastrointestinal bleed by portal hypertension (4 days required for stable condition)
  • Active sepsis (4 days required for stable condition)
  • Patient currently treated by antibiotic
  • Concomitant Liver cancer (HCC) or extrahepatic malignancy
  • Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine >221 μmol/L (>2.5 mg/dL) or the requirement for renal replacement therapy
  • Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria
  • Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory support (ie, endotracheal intubation or positive-pressure ventilation)
  • Disseminated intravascular coagulation
  • Intestinal paralysis
  • History of liver transplantation

Other general diseases or severe conditions:

  • HIV disease
  • Intestinal paralysis
  • Intestinal inflammatory disease (Crohn or Ulcerative colitis)
  • Clostridium difficilae infection
  • Clinical suspicion of pneumonia
  • Uncontrolled sepsis
  • Acute Alcoholic pancreatitis
  • Noncontrolled alcohol withdrawal syndrome
  • Cardiac or respiratory bad conditions

Treatment and study plan

stool withdrawal

Other

stool withdrawal at day 0 and day 7

Primary outcomes

  1. variation of sample bacterial composition between the three groups

    Time frame: day 7

Study contacts

Contact information is provided by the study sponsor or research team.

Eric Nguyen-Khac, Pr

CONTACT

[email protected]

0322088851

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Collaborators

  • CH Montdidier

Registry information

Official study title

Intestinal Microbiota Profiling in HAA Patients

Acronym: HepathAlc-IM

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Dec 6, 2023
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.